Scribe Therapeutics (SCTX) 10% Owner Behzad Aghazadeh Buys Stock

What Happened

• Behzad Aghazadeh, reported as a 10% owner through affiliated funds, made purchases of Scribe Therapeutics (SCTX) common stock between July 24 and July 28, 2026. Total purchases: 2,391,238 shares for an aggregate purchase price of $36,259,761.
  • 2,333,333 shares at $15.00 each on 2026-07-24 — purchased from underwriters at the IPO price (total $34,999,995).
  • 50,000 shares at $22.31 each on 2026-07-24 (open-market) — $1,115,500.
  • 7,905 shares at $18.25 each on 2026-07-28 (open-market) — $144,266.
• These are purchases (transaction code P), a straightforward buy signal rather than a sale.

Key Details

• Transaction dates & prices: 7/24/2026 — 2,333,333 @ $15.00 and 50,000 @ $22.31; 7/28/2026 — 7,905 @ $18.25.
• Shares reported owned after these transactions: 3,088,888 total — 2,598,973 held by Avoro Life Sciences and 489,915 held by Avoro Ventures.
• Notable items from the filing:
  • The large $15.00 tranche was bought from IPO underwriters; other purchases were open-market (footnotes F1 & F2).
  • The reported ownership total includes 697,650 shares issued upon automatic conversion of Series B preferred shares at the IPO closing (footnote F6).
  • Securities are held directly by Avoro Life Sciences Fund LLC and Avoro Ventures Fund L.P.; Avoro Capital Advisors and Avoro Ventures act as advisers, and Dr. Aghazadeh is the portfolio manager/controlling person (footnote F4). The reporting persons disclaim direct beneficial ownership except to the extent of pecuniary interest (footnote F5).
• Filing timeliness: Form 4 was filed July 28, 2026 reporting trades dated July 24–28; the filing shows no late-report flag.

Context

• These purchases were made by investment funds advised/managed by Aghazadeh (institutional purchases), not necessarily personal trading — retail investors should treat this as fund-level buying rather than an individual executive signaling.
• The IPO-related allocation and conversion of preferred shares increased the reported common share holdings automatically at IPO close; no separate conversion transaction is listed because conversion occurred upon IPO closing.